Condition
EGFR-mutant Non-small Cell Lung Cancer
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Unknown1
Active Not Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03333343Phase 1Active Not RecruitingPrimary
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
NCT07323056Phase 2RecruitingPrimary
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
NCT03904823Phase 2UnknownPrimary
A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC
Showing all 3 trials